Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including damaged DNA. We investigated the effect of pharmacological inhibition of c-Abl on the processing of irradiation-induced DNA damage in Bcr-Abl-negative cells. Cell lines and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were treated with imatinib or dasatinib before γ-irradiation. Inhibition of c-Abl caused an enhanced irradiation-induced mutation frequency and slowdown of DNA repair, whereas imatinib was ineffective in cells expressing a T315I variant of c-Abl. Mutation frequency and repair kinetics were also studied in c-Abl−/− murine embryonic fibroblasts (MEFs) retransfected with wild-type c-Abl (wt-Abl) or a kinase-defect variant of Abl (KD-Abl). Enhanced mutation frequency as well as delayed DNA repair was observed in cells expressing KD-Abl. These data indicate that pharmacological inhibition of c-Abl compromises DNA-damage response.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . (2002). Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16: 1390–1393.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100–104.
Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG et al. (1999). Mutator phenotype of BCR–ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 18: 2676–2680.
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB et al. (1997). CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947–4952.
Cheng WH, von Kobbe C, Opresko PL, Fields KM, Ren J, Kufe D et al. (2003). Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol 23: 6385–6395.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561–566.
Foray N, Marot D, Randrianarison V, Venezia ND, Picard D, Perricaudet M et al. (2002). Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation. Mol Cell Biol 22: 4020–4032.
Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA et al. (2002). Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 21: 3715–3727.
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925–932.
Imam SZ, Indig FE, Cheng WH, Saxena SP, Stevnsner T, Kufe D et al. (2007). Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase. Nucleic Acids Res 35: 4941–4951.
Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908–916.
Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM et al. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386: 732–735.
Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D . (1998). Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17: 3309–3318.
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. (2005). Dynamics of chronic myeloid leukaemia. Nature 435: 1267–1270.
Moehring A, Wohlbold L, Aulitzky WE, van der Kuip H . (2005). Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death. Cell Death Differ 12: 627–636.
Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496–3499.
Salloukh HF, Laneuville P . (2000). Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 14: 1401–1404.
Shaul Y, Ben-Yehoyada M . (2005). Role of c-Abl in the DNA damage stress response. Cell Res 15: 33–35.
Singh NP, McCoy MT, Tice RR, Schneider EL . (1988). A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184–191.
Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C et al. (2004). Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18: 1340–1346.
Uemura N, Griffin JD . (2000). The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood 96: 3294–3295.
van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE . (2004). Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. Leuk Res 28: 405–408.
Wang JY . (2000). Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643–5650.
Wei G, Li AG, Liu X . (2005). Insights into selective activation of p53 DNA binding by c-Abl. J Biol Chem 280: 12271–12278.
Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S et al. (1998). Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 273: 3799–3802.
Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. (1999). p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814–817.
We are grateful to Tabea Peußer and Kerstin Willecke for technical assistance. The MEFs were a kind gift from Dr JY Wang (UCSD, San Diego, CA, USA).
Research Grants and other Financial Support: This work was financially supported by the Robert Bosch foundation project O2A and the Deutsche Forschungsgemeinschaft project KU 2338/1-1.
About this article
Cite this article
Fanta, S., Sonnenberg, M., Skorta, I. et al. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 27, 4380–4384 (2008). https://doi.org/10.1038/onc.2008.68
This article is cited by
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
Cell Death & Disease (2014)
Cell Death & Differentiation (2011)
Cell Death & Disease (2010)
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features